LENZ Therapeutics Inc
LENZ14.220USD
+0.250+1.79%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
406.53M시가총액
손실P/E TTM
자세한 내용은 LENZ Therapeutics Inc 회사
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Inc 정보
종목 코드 LENZ
회사 이름LENZ Therapeutics Inc
상장일Jun 25, 2021
CEOSchimmelpennink (Evert)
직원 수42
유형Ordinary Share
회계 연도 종료Jun 25
주소- -
도시- -
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가- -
우편 번호- -
전화- -
웹사이트- -
종목 코드 LENZ
상장일Jun 25, 2021
CEOSchimmelpennink (Evert)
LENZ Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+10500.00%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+2198.00%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+10500.00%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+2198.00%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sun, Feb 1
마지막 업데이트: Sun, Feb 1
주주
주주 유형
주주
주주
비율
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
UBS Financial Services, Inc.
5.02%
기타
55.35%
주주
주주
비율
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
UBS Financial Services, Inc.
5.02%
기타
55.35%
주주 유형
주주
비율
Venture Capital
34.63%
Investment Advisor
30.67%
Hedge Fund
23.82%
Investment Advisor/Hedge Fund
17.10%
Individual Investor
2.52%
Research Firm
2.00%
Pension Fund
0.23%
Bank and Trust
0.13%
Insurance Company
0.02%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
308
33.89M
108.31%
+1.02M
2025Q3
267
30.95M
100.67%
+981.38K
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
UBS Financial Services, Inc.
881.48K
3.09%
+214.32K
+32.12%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Tang Capital Management, LLC
897.62K
3.15%
+130.68K
+17.04%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
State Street SPDR S&P Pharmaceuticals ETF
1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
0.27%
iShares U.S. Pharmaceuticals ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.06%
더 보기
State Street SPDR S&P Pharmaceuticals ETF
비율1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
비율1.04%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
비율0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.27%
iShares U.S. Pharmaceuticals ETF
비율0.22%
ProShares Ultra Nasdaq Biotechnology
비율0.11%
iShares Micro-Cap ETF
비율0.09%
Invesco Nasdaq Biotechnology ETF
비율0.08%
iShares Biotechnology ETF
비율0.06%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
날짜
배당락일
유형
비율
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
